Camurus AB

Good day everyone and thank you for taking the time to join our first earnings call for 2024. So before starting the presentation please notice our forward looking statements. So the agenda for today's call includes first quarter highlights, financial results, we will then move to commercial and pipeline updates and finish off with a Q&A. And with me on the call today, as previously, are John Garay, our chief financial officer, and Richard Jameson, our chief commercial officer. So starting out with our highlights in the quarter, cameras had a productive first quarter with strong profitability and pipeline progress. Total revenues grew by 37% year-on-year to 390 million SEC, which is the midpoint of our provided guidance. with profit before tax in the quarter of close to 100 million SEC. Our financial position was further strengthened by a successful directed share issue to support inorganic growth opportunities to accelerate U.S.

commercial preparations for CAM 2023. and neuroendocrine tumors and polycystic liver disease, and enhance our manufacturing capabilities. From a commercial perspective, we continue strengthening our leading position in opioid dependence treatment across geographies, Juvenile sales increased by 29% year-on-year to $364 million at reported rates. In the U.S., Bricsad shows strong and accelerating growth, resulting in an approximate threefold the increase in sales and reliability in the first quarter versus Q4 of 2023. So on the R&D side, we received FDA acceptance for the review of NDA Proclays in in October this year. The corresponding application has now been submitted to the FEMA, and outside the Afgromegaly area, We progressed the surrender study of CAM 2029 in Rwanda and completed patient recruitment in the positive terminal class. including completing Preclinical assessments of non-verbal and non-multiple formulations of stem microtypes. We are preparing for our first clinical study, planned to be started towards the end of this year.

And with this short introduction, I will hand over to John for the finances.